Loading

Nivolumab (Opdivo®)

Dokument Fact Sheet
Spezifizierung Lungenkarzinom, nicht-kleinzellig (NSCLC) » + Ipilimumab (Yervoy®) » Kombination, Erstlinie
Stand Juli 2021
Dies ist die aktuell gültige Version des Dokuments

1Nivolumab+Ipilimumab, NSCLC, combination, first line

1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/414 results for control, results for new therapy15 hazard ratio for new therapy

Kommentare